290 related articles for article (PubMed ID: 9871680)
1. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.
Adams J; Behnke M; Chen S; Cruickshank AA; Dick LR; Grenier L; Klunder JM; Ma YT; Plamondon L; Stein RL
Bioorg Med Chem Lett; 1998 Feb; 8(4):333-8. PubMed ID: 9871680
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition: a novel approach to cancer therapy.
Adams J
Trends Mol Med; 2002; 8(4 Suppl):S49-54. PubMed ID: 11927288
[TBL] [Abstract][Full Text] [Related]
3. Promoting proteasomes: trash to treasure.
Sussman HE
Drug Discov Today; 2003 Oct; 8(19):866-8. PubMed ID: 14554007
[No Abstract] [Full Text] [Related]
4. TMC-95A, a reversible proteasome inhibitor, induces neurite outgrowth in PC12 cells.
Inoue M; Zhai H; Sakazaki H; Furuyama H; Fukuyama Y; Hirama M
Bioorg Med Chem Lett; 2004 Feb; 14(3):663-5. PubMed ID: 14741264
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of the chymotrypsin-like activity of the 20S proteasome by 5-methoxy-1-indanone dipeptide benzamides.
Lum RT; Nelson MG; Joly A; Horsma AG; Lee G; Meyer SM; Wick MM; Schow SR
Bioorg Med Chem Lett; 1998 Feb; 8(3):209-14. PubMed ID: 9871656
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitors: valuable new tools for cell biologists.
Lee DH; Goldberg AL
Trends Cell Biol; 1998 Oct; 8(10):397-403. PubMed ID: 9789328
[TBL] [Abstract][Full Text] [Related]
7. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
[TBL] [Abstract][Full Text] [Related]
8. Cancer research. Taking garbage in, tossing cancer out?
Garber K
Science; 2002 Jan; 295(5555):612-3. PubMed ID: 11809952
[No Abstract] [Full Text] [Related]
9. Synthesis, in vitro and in vivo biological evaluation, docking studies, and structure--activity relationship (SAR) discussion of dipeptidyl boronic acid proteasome inhibitors composed of beta-amino acids.
Zhu Y; Zhu X; Wu G; Ma Y; Li Y; Zhao X; Yuan Y; Yang J; Yu S; Shao F; Li R; Ke Y; Lu A; Liu Z; Zhang L
J Med Chem; 2010 Mar; 53(5):1990-9. PubMed ID: 20158184
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibitors for cancer therapy.
Iqbal M; Messina McLaughlin PA; Dunn D; Mallya S; Husten J; Ator MA; Chatterjee S
Bioorg Med Chem; 2012 Apr; 20(7):2362-8. PubMed ID: 22377673
[TBL] [Abstract][Full Text] [Related]
11. P'-extended alpha-ketoamide inhibitors of proteasome.
Chatterjee S; Dunn D; Mallya S; Ator MA
Bioorg Med Chem Lett; 1999 Sep; 9(17):2603-6. PubMed ID: 10498217
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of the chymotrypsin-like activity of proteasome based on di- and tri-peptidyl alpha-keto aldehydes (glyoxals).
Lynas JF; Harriott P; Healy A; McKervey MA; Walker B
Bioorg Med Chem Lett; 1998 Feb; 8(4):373-8. PubMed ID: 9871688
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibition induces cytokeratin accumulation in vivo.
Bardag-Gorce F; Vu J; Nan L; Riley N; Li J; French SW
Exp Mol Pathol; 2004 Apr; 76(2):83-9. PubMed ID: 15010285
[TBL] [Abstract][Full Text] [Related]
15. N-Terminal peptidic boronic acids selectively inhibit human ClpXP.
Knott K; Fishovitz J; Thorpe SB; Lee I; Santos WL
Org Biomol Chem; 2010 Aug; 8(15):3451-6. PubMed ID: 20523950
[TBL] [Abstract][Full Text] [Related]
16. Potent inhibitors of proteasome.
Iqbal M; Chatterjee S; Kauer JC; Das M; Messina P; Freed B; Biazzo W; Siman R
J Med Chem; 1995 Jun; 38(13):2276-7. PubMed ID: 7608891
[No Abstract] [Full Text] [Related]
17. Proteasome inhibition enhances lipofuscin formation.
Terman A; Sandberg S
Ann N Y Acad Sci; 2002 Nov; 973():309-12. PubMed ID: 12485885
[TBL] [Abstract][Full Text] [Related]
18. [Proteasome inhibitors].
Hatake K; Mishima Y; Terui Y
Gan To Kagaku Ryoho; 2004 Jul; 31(7):999-1002. PubMed ID: 15272575
[TBL] [Abstract][Full Text] [Related]
19. The core structure of TMC-95A is a promising lead for reversible proteasome inhibition.
Kaiser M; Groll M; Renner C; Huber R; Moroder L
Angew Chem Int Ed Engl; 2002 Mar; 41(5):780-3. PubMed ID: 12491334
[No Abstract] [Full Text] [Related]
20. Apoptosis meets proteasome, an invaluable therapeutic target of anticancer drugs.
Giuliano M; D'Anneo A; De Blasio A; Vento R; Tesoriere G
Ital J Biochem; 2003 Jun; 52(2):112-21. PubMed ID: 14677428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
